Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, April 4, 2022
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
Sun, April 3, 2022
Fri, April 1, 2022
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
Chris Shibutani Downgraded (AMLX) to Hold and Decreased Target to $10 on, Apr 1st, 2022
Chris Shibutani of Goldman Sachs, Downgraded "Amylyx Pharmaceuticals, Inc." (AMLX) to Hold and Decreased Target from $36 to $10 on, Apr 1st, 2022.
Chris has made no other calls on AMLX in the last 4 months.
There are 3 other peers that have a rating on AMLX. Out of the 3 peers that are also analyzing AMLX, 0 agree with Chris's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Chris
- Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $31 on, Thursday, March 31st, 2022
- Umer Raffat of "Evercore ISI Group" Initiated at Buy on, Wednesday, February 2nd, 2022
- Andrew Fein of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $35 on, Tuesday, February 1st, 2022
